These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779 [TBL] [Abstract][Full Text] [Related]
7. siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Lu PY; Xie FY; Woodle MC Curr Opin Mol Ther; 2003 Jun; 5(3):225-34. PubMed ID: 12870431 [TBL] [Abstract][Full Text] [Related]
8. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651 [TBL] [Abstract][Full Text] [Related]
9. RNA interference for the treatment of cancer. Putral LN; Gu W; McMillan NA Drug News Perspect; 2006; 19(6):317-24. PubMed ID: 16971967 [TBL] [Abstract][Full Text] [Related]
10. Nonviral in vivo delivery of therapeutic small interfering RNAs. Aigner A Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447 [TBL] [Abstract][Full Text] [Related]
11. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Yagi N; Manabe I; Tottori T; Ishihara A; Ogata F; Kim JH; Nishimura S; Fujiu K; Oishi Y; Itaka K; Kato Y; Yamauchi M; Nagai R Cancer Res; 2009 Aug; 69(16):6531-8. PubMed ID: 19654315 [TBL] [Abstract][Full Text] [Related]
12. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters). Vandenbroucke RE; De Geest BG; Bonné S; Vinken M; Van Haecke T; Heimberg H; Wagner E; Rogiers V; De Smedt SC; Demeester J; Sanders NN J Gene Med; 2008 Jul; 10(7):783-94. PubMed ID: 18470950 [TBL] [Abstract][Full Text] [Related]
13. Targeted quantum dot conjugates for siRNA delivery. Derfus AM; Chen AA; Min DH; Ruoslahti E; Bhatia SN Bioconjug Chem; 2007; 18(5):1391-6. PubMed ID: 17630789 [TBL] [Abstract][Full Text] [Related]
14. A review of nanocarriers for the delivery of small interfering RNA. Kesharwani P; Gajbhiye V; Jain NK Biomaterials; 2012 Oct; 33(29):7138-50. PubMed ID: 22796160 [TBL] [Abstract][Full Text] [Related]
15. Advances in the development of siRNA-based therapeutics for cancer. Shen Y IDrugs; 2008 Aug; 11(8):572-8. PubMed ID: 18683092 [TBL] [Abstract][Full Text] [Related]
16. Bioreducible polymers for efficient gene and siRNA delivery. Jere D; Arote R; Jiang HL; Kim YK; Cho MH; Cho CS Biomed Mater; 2009 Apr; 4(2):025020. PubMed ID: 19349651 [TBL] [Abstract][Full Text] [Related]
17. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. García-Castro J; Martínez-Palacio J; Lillo R; García-Sánchez F; Alemany R; Madero L; Bueren JA; Ramírez M Cancer Gene Ther; 2005 Apr; 12(4):341-9. PubMed ID: 15650763 [TBL] [Abstract][Full Text] [Related]
18. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770 [TBL] [Abstract][Full Text] [Related]
19. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Jonson AL; Rogers LM; Ramakrishnan S; Downs LS Gynecol Oncol; 2008 Nov; 111(2):356-64. PubMed ID: 18755502 [TBL] [Abstract][Full Text] [Related]
20. Cancer, chitosan nanoparticles and catalytic nucleic acids. Tan ML; Choong PF; Dass CR J Pharm Pharmacol; 2009 Jan; 61(1):3-12. PubMed ID: 19126291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]